Date: 2017-11-02
Type of information: Restructuring
Company: 20Med Therapeutics (NL)
Investors: Twente Technology Fund (TTF) (NL), Oost NL (NL),
Amount:
Funding type:
Planned used:
The funds will be used to accelerate the development of the 20Med Nanogel technology towards human applications. 20Med is building a pipeline of oligonucleotide therapeutics
based on the 20Med delivery technology, with an initial focus on hereditary retinal diseases.
In addition, 20Med will continue and expand its collaborations with leading pharma and biotech companies on the intracellular delivery of RNA therapeutics for a wide range of indications.
20Med Therapeutics’ proprietary Nanogel technology has been developed specifically for the intracellular delivery of oligonucleotides. Based on bioresponsive polymers, the
nanoparticle technology has been fine-tuned to overcome all major hurdles in intracellular delivery. The bioresponsive nanoparticles allow for efficient transfection, endosomal escape and release of the payload into the cytosol. The 20Med Nanogels can be easily manufactured, freeze-dried and stored for extended periods of time. They can be loaded
post-manufacturing with a wide range of oligonucleotide based products (DNA, siRNA, mRNA, miRNA or ASOs), making the 20Med Nanogels an excellent and cost-effective
alternative for viral or LNP based delivery systems.
Others:
20Med Therapeutics secures new financing for accelerated development
of the 20Med Nanogel technology for the delivery of RNA therapeutics
Enschede, The Netherlands, November 2, 2017 – Dutch biotechnology company 20Med
Therapeutics has secured new financing for further development of the 20Med Nanogel
technology for the delivery of RNA therapeutics. The financing round was led by a group of
private investors in combination with founding investor Twente Technology Fund (TTF).
Oost NL also participated through regional innovation fund Innovatiefonds Twente (IFT).
The funds will be used to accelerate the development of the 20Med Nanogel technology
towards human applications. 20Med is building a pipeline of oligonucleotide therapeutics
based on the 20Med delivery technology, with an initial focus on hereditary retinal diseases.
In addition, 20Med will continue and expand its collaborations with leading pharma and
biotech companies on the intracellular delivery of RNA therapeutics for a wide range of
Therapeutic area:
